Lactobacillus Crispatus
Phase 2Small molecule
Lactobacillus Crispatus is one of 3 small molecule programs targeting RCT. It is currently in Phase 2.
1
Indications
6
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in RCT
#DrugCompanyPhaseTrials
1Lynparza
AstraZenecaPhase 3
Lactobacillus Crispatus
MMedstar Health Research Institute
Phase 2
Foam Sclerotherapy
IImperial College London
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Keratoconjunctivitis1 trial
Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment
Completed·—·Phase 2/3·NCT00445120·48 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lactobacillus Crispatus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details